Clinical, manufacturing, safety, and commercial teams all lean on shared data. They need to agree on who publishes each data product, who can use it, and what evidence goes with it.
|Articles|March 2, 2018
Fette Compacting America
The FEC40 Capsule Filler can produce up to 400,000 capsules/hr-nearly twice the volume of any competitor.
Advertisement
The FEC40 Capsule Filler can produce up to 400,000 capsules/hr-nearly twice the volume of any competitor. Its remarkably small footprint makes machine reconfiguration due to floor space issues unnecessary. Extraordinarily high performance-to-footprint ratio is made possible by Fette Compacting’s patented Duplex Concept, enabling FEC40 to feature a dual capsule filling process. The result is significant production savings (up to 30% per 1000 capsules).
400 Forge Way, Rockaway, NJ 07866
tel. 973.586.8722
INTERPHEX Booth Number: 2505C
Advertisement
Related to this article
Structural modifications can improve peptide stability, solubility, and absorption to enable effective oral delivery.
The FDA approves VOCERYQ, the first DNA medicine, for RRP surgery reduction, raising plasmid, drug-device, and confirmatory trial manufacturing demands.
Continuous overall equipment effectiveness can be used to pinpoint hidden downtime and process bottlenecks in real time.
Subathra Ramamoorthy, Veranova, on how forced degradation and trace impurity profiling in potent APIs shape regulator-ready analytical methods.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
2
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
3
1074 Revision Needs Formulator Feedback: AAPS PharmSci 360 2026
4
AAPS PharmSci 360 2026: Spray Drying and ASD
5